CrossrefInfokarte
Pharmacokinetics, Safety, Tolerability, and Immunogenicity of BP02 (Trastuzumab Biosimilar) Compared to EU- and US-Approved Trastuzumab in Healthy Adult Male Volunteers: A Phase 1, Randomized, Double-Blind Study
Oncology and Therapy · 2024-09 · 12 (3) · 477-490
DOI: 10.1007/s40487-024-00289-0 ↗Abstract
Kein Abstract verfügbar.
EUVIMED